News about Intuitive Surgical

Three Wall Street analysts at Oppenheimer, Citigroup and Baird see Intuitive Surgical (ISRG) reaching $500 per share. Oppenheimer upgraded the stock to Outperform in August with a $500 target, while Citigroup and Baird cut their targets to $500 in July but kept Buy and Outperform ratings. The article cites growth from recurring revenue: in the second quarter of 2026 the company placed 246 da Vinci 5 systems versus 180 a year earlier, procedures rose 15%, and instrument and accessory revenue climbed 18% to roughly $1.7 billion. Key risks include slower procedure growth, tight hospital budgets and rising competition, and the stock's P/E of about 49 leaves little room for disappointment. A consensus of 31 analysts rates it Strong Buy, with targets implying 12% to 60% upside, and third-quarter results are expected around Oct. 20.